Senti Biosciences Holdings (SNTI) Other financing activities (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Other financing activities of -$2.5 million for Q4 2025, down 202.02% year-over-year from $2.5 million in Q4 2024, and down 349.5% quarter-over-quarter from $1.0 million in Q2 2025.
Senti Biosciences Holdings (SNTI) Other financing activities (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Other financing activities history runs 4 years deep, the most recent figure standing at -$2.5 million for Q4 2025.
- In Q4 2025, Other financing activities fell 202.02% year-over-year to -$2.5 million; the TTM figure through Sep 2025 stood at $5.0 million (up 105.35% YoY), while the FY2024 annual figure was $4.9 million, changed N/A from the prior year.
- Other financing activities for Q4 2025 stood at -$2.5 million, down from $1.0 million in the prior quarter.
- The five-year high for Other financing activities was $225.4 million in Q2 2021, with the low at -$111.9 million in Q3 2022.
- The 4-year median for Other financing activities is $2.4 million (2024), against an average of $22.3 million.
- Peak annual rise in Other financing activities reached 50.17% in 2022, while the deepest fall reached 1664.54% in 2022.
- Senti Biosciences Holdings' Other financing activities stood at $7.2 million in 2021, then slumped by 1664.54% to -$111.9 million in 2022, then soared by 102.21% to $2.5 million in 2024, then sank by 202.02% to -$2.5 million in 2025.
- Business Quant data shows SNTI's Other financing activities at -$2.5 million in Q4 2025, $1.0 million in Q2 2025, and $1.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.52 Mn |
| Dec 31, 2025 | -2.52 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Sep 30, 2022 | -111.94 Mn |
| Sep 30, 2022 | -111.94 Mn |
| Jun 30, 2022 | 112.32 Mn |
| Jun 30, 2022 | 112.32 Mn |
| Mar 31, 2022 | 140,000.00 |
| Mar 31, 2022 | 140,000.00 |
| Dec 31, 2021 | 7.16 Mn |
| Dec 31, 2021 | 7.16 Mn |
| Sep 30, 2021 | 7.16 Mn |
| Sep 30, 2021 | 7.16 Mn |